Phase III Study Comparing Digital Telemonitoring Platform Cureety TechCare to Standard Care in Adults With Metastatic Triple-Negative Breast Cancer Starting First-line Treatment

What this Trial Is About

The trial investigates whether adding a digital telemonitoring platform called CUREETY TECHCARE to the usual care can improve outcomes for patients with metastatic triple-negative breast cancer who have not received prior treatment and are starting their first systemic therapy. It aims to understand if telemonitoring can enhance patient quality of life, reduce hospitalization rates, and improve overall survival compared to standard care alone. Participants in the telemonitoring group will use the Cureety platform weekly to report symptoms. The platform analyzes these symptoms and classifies the patients condition into risk categories, which guide tailored advice and alerts for medical staff. The medical team monitors patients daily via the platform and adjusts care as needed. The comparison group receives standard care without telemonitoring. During the study, patients complete quality of life questionnaires at baseline and regular intervals up to 24 months. Researchers will track time to quality of life deterioration, hospitalization-free survival, and overall survival as primary outcomes. Secondary outcomes include treatment toxicity, treatment failure, clinical deterioration, adverse events, treatment compliance, satisfaction with telemonitoring, and socio-economic impacts. The study involves ongoing monitoring, data collection, and patient questionnaires over two years to assess the benefits and effects of telemonitoring.

Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment